Results 131 to 140 of about 1,862 (162)

Unmasking the Prodrome: A Deep-Learning Bridge to Precision Diagnostics in Rapid Eye Movement Sleep Behavior Disorder. [PDF]

J Clin Neurol
Kwon KY.
europepmc   +1 more source

Association of DTI-ALPS Glymphatic Index With Differential Phenoconversion in Isolated REM Sleep Behavior Disorder: A Multi-Cohort MRI Study. [PDF]

Neurology
Ayral V, Pastor-Bernier A, Daneault V, Tremblay C, Filiatrault M, Haddad C, Gagnon JF, Postuma RB, Dušek P, Marecek S, Varga Z, Klein JC, Hu MT, Lehéricy S, Arnulf I, Vidailhet M, Corvol JC, ICEBERG Study Group, Rahayel S.   +18 more
europepmc   +1 more source

Glymphatic Function in Prodromal Parkinson's Disease: Associations With Symptoms, Gray Matter Volume, and Phenoconversion Risk. [PDF]

Eur J Neurol
Chen A, Kuang Z, Khong PL, Huang J, Wen J, Choi YS, Xu Y, Wu P, Wei X.   +8 more
europepmc   +1 more source

Actionable medications in Australian Vietnam War veterans: Implications for pre-emptive pharmacogenetic testing. [PDF]

Australas Psychiatry
Tan WLA, Mellor R, Bennett D, Shu D, Leite de Castro CWS, Voisey J, Guindalini C, Semmler A.   +7 more
europepmc   +1 more source

A Comprehensive Analysis Examining the Role of Genetic Influences on Psychotropic Medication Response in Children. [PDF]

Genes (Basel)
Singh J, Manginas A, Wilkins G, Santosh P.   +3 more
europepmc   +1 more source

Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review [PDF]

Journal of Clinical Medicine, 2020
Phenoconversion is the mismatch between the individual’s genotype-based prediction of drug metabolism and the true capacity to metabolize drugs due to nongenetic factors. While the concept of phenoconversion has been described in narrative reviews, no systematic review is available.
Sylvia Klomp, Jesse J Swen, Martijn Manson   +2 more
exaly   +6 more sources

Some of the next articles are maybe not open access.

Related searches:

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine

Expert Opinion on Drug Metabolism and Toxicology, 2022
CYP2D6 contributes to the metabolism of approximately 20-25% of drugs. However, CYP2D6 is highly polymorphic and different alleles can lead to impacts ranging from null to increase in activity. Moreover, there are commonly used drugs that potently inhibit the CYP2D6, thus causing 'phenoconversion' which can convert the genotypic normal metabolizer into
Julie Johnson
exaly   +3 more sources